logo-loader
viewCytoDyn Inc.

CytoDyn to begin proof-of-concept studies for leronlimab to treat liver damage caused by NASH

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive Investors that the Cleveland Clinic will evaluate if its flagship drug leronlimab can prevent Non-Alcoholic Steatohepatitis (NASH), or "fatty liver" in mice.

Pourhassan says the Vancouver, Washington-based company will begin proof-of-concept studies of leronlimab in NASH in an 'expedited' fashion.

Quick facts: CytoDyn Inc.

Price: 2.97 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $1.43 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CytoDyn to work with Mexican National Institutes of Health to treat...

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan tells Proactive the biotech has plans to work with the Mexican National Institutes of Health on a trial of leronlimab for severe coronavirus patients in the country. Pourhassan says the initial trial is expected to include about 30 patients. After...

1 week, 6 days ago

2 min read